Financing ·
Pacific Biosciences enters ATM equity offering for up to $100M through Allen & Company
PACBPacific Biosciences of California, Inc.
On November 10, 2026, Pacific Biosciences of California, Inc. entered into a Sales Agreement with Allen & Company LLC to sell shares of its common stock having aggregate sales proceeds of up to $100 million through an at-the-market equity offering program. The company retains the right to set parameters for sales, including volume and pricing limits, while Allen acts as sales agent for a commission of up to 3.0% of gross proceeds. This offering is conducted under the company's existing automatic shelf registration statement on Form S-3ASR. Pacific Biosciences develops and sells genomic analysis systems and reagents.